Itoh H, Zheng J, Bird I M, Nakao K, Magness R R
Department of Obstetrics and Gynecology, Perinatal Research Laboratories, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.
Am J Physiol. 1999 Aug;277(2):R541-7. doi: 10.1152/ajpregu.1999.277.2.R541.
Atrial natriuretic peptide (ANP) is present in the fetoplacental circulation of humans and sheep. The ANP-A receptor is the specific membrane receptor for ANP, which produces cGMP. The clearance receptor of natriuretic peptide (CR) is postulated to modulate local concentrations of ANP, thereby modulating cGMP production through the ANP-A receptor. Recently we reported that fetoplacental basic fibroblast growth factor (bFGF) and cGMP levels are increased dramatically during the third trimester of ovine gestation. Therefore we hypothesized that bFGF will downregulate CR expression in cultured ovine fetoplacental artery endothelial (OFPAE) cells via the mitogen-activated protein kinase (MAPK) signal cascade mechanism, thereby causing augmentation of ANP-mediated cGMP production. Western analysis and/or RT-PCR of CR expression were performed after treatment of OFPAE cells with bFGF (10 pg/ml-1 microgram/ml) with or without 50 microM PD-98059, a selective inhibitor of MAPK kinase. To investigate the possible effects of CR downregulation on the functional modulation of ANP-A receptor activation, cGMP production (20 min) by OFPAE cells was measured in response to ANP (10 pM-1 microM) with or without pretreatment (24 h) of 10 ng/ml bFGF. CR expression in OFPAE cells was dose dependently downregulated by 1-10 ng/ml bFGF treatment (maximum -69%), which was completely reversed by pretreatment with PD-98059. Treatment of OFPAE cells with 10 ng/ml bFGF (24 h) did not alter maximum ANP-A activity (cGMP production/20 min), but decreased the apparent ED(50) of ANP to stimulate cGMP production from 2.5 to 0.83 nM, suggesting the possibility that bFGF-mediated downregulation of CR may elevate ANP-mediated cGMP production responses. Thus bFGF downregulates CR mRNA and protein expressions via the MAPK cascade in OFPAE cells.
心房利钠肽(ANP)存在于人类和绵羊的胎儿 - 胎盘循环中。ANP - A受体是ANP的特异性膜受体,可产生环磷酸鸟苷(cGMP)。利钠肽清除受体(CR)被认为可调节局部ANP浓度,从而通过ANP - A受体调节cGMP的产生。最近我们报道,在绵羊妊娠晚期,胎儿 - 胎盘碱性成纤维细胞生长因子(bFGF)和cGMP水平显著升高。因此,我们推测bFGF将通过丝裂原活化蛋白激酶(MAPK)信号级联机制下调培养的绵羊胎儿 - 胎盘动脉内皮(OFPAE)细胞中的CR表达,从而导致ANP介导的cGMP产生增加。在用或不用50μM PD - 98059(一种MAPK激酶的选择性抑制剂)处理OFPAE细胞后,用bFGF(10 pg/ml - 1μg/ml)进行CR表达的蛋白质免疫印迹分析和/或逆转录 - 聚合酶链反应(RT - PCR)。为了研究CR下调对ANP - A受体激活功能调节的可能影响,在用或不用10 ng/ml bFGF预处理(24小时)的情况下,测量OFPAE细胞对ANP(10 pM - 1μM)的cGMP产生(20分钟)。1 - 10 ng/ml bFGF处理可使OFPAE细胞中的CR表达呈剂量依赖性下调(最大下调69%),而用PD - 98059预处理可完全逆转这种下调。用10 ng/ml bFGF处理OFPAE细胞(24小时)不会改变最大ANP - A活性(cGMP产生/20分钟),但会将ANP刺激cGMP产生的表观半数有效浓度(ED50)从2.5 nM降至0.83 nM,这表明bFGF介导的CR下调可能会提高ANP介导的cGMP产生反应。因此,bFGF通过MAPK级联在OFPAE细胞中下调CR mRNA和蛋白质表达。